The global Alzheimer’s treatment market is expected to grow at a CAGR of 7.2% in 2023-2031 and is projected to reach about 80.2 billion USD by 2031. The market is driven by the increased elderly population and increasing immune disorders are the major cause of the disease's high prevalence. Another vital factor projected to influence the industry growth is the increasing government investment for improved support and care for those with progressive Alzheimer’s.
Another vital factor projected to influence the industry growth is the increasing government investment for improved support and care for those with progressive Alzheimer’s.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Alzheimer's disease is among the most prominent form of dementia, a type of progressive cognitive disorder. It is a disease is a progressive neurodegenerative disorder that leads to atrophy and the brain cells eventually die.
Brain cell deterioration significantly affects the person's ability to function without being dependent on anyone. Initial symptoms of Alzheimer’s are minor memory loss and confusion. These early symptoms are frequently missed because they are misinterpreted as signs of the natural ageing process or exhaustion. As the disease progresses, the symptoms progress to a stage where it becomes impossible to function without proper care. The mild symptom of Alzheimer’s includes lack of spontaneity, subtle personality change, and minor disorientation. The symptoms tend to get worse as the disease progresses.
The symptoms of Alzheimer’s disease progress to the point where the patient begins to experience drastic personality changes as they become incapable of comprehending normal day-to-day activities. Patients lose cognitive abilities, exhibit repetitive behaviour, and have no control over their appetite. Patients also lack self-control and are completely dependent on caregivers for both voluntary and involuntary bodily functions such as bladder control and bowel movements, decreased response to the environment, emaciation, seizures, and so forth.
The disease is idiopathic, and the exact cause is still to be known. However, Alzheimer’s disease can be caused by a variety of factors, including increasing age, genetic factors, Down syndrome, head trauma, insomnia, a poor lifestyle, mild cognitive impairment (MCI), and excessive alcohol and drug consumption. Although there is no current cure for Alzheimer’s disease, several new therapeutic techniques have been developed to combat the disease. The major diagnostics and therapeutics involved in the Alzheimer’s disease industry include the development of biomarkers for Alzheimer’s diagnosis. While some treatments may postpone clinical decline and improve cognition and function, disease progression and eventual cell death cannot be prevented with current treatments.
The present treatments may assist in alleviating symptoms such as memory loss and confusion. The Alzheimer's disease market is expected to grow as more drugs are developed to cure and treat the disease. The rising awareness-raising initiatives by public and private organisations will influence the Alzheimer's disease market in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Alzheimer’s Disease Treatment is segmented into:
Based on drug class, the market is segmented into
Based on the diagnosis, the market is segmented into
Based on the treatment channel, the market is bifurcated into
Based on age, the market is segmented into
Based on the End User, the market is segmented into
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Alzheimer’s disease has a high prevalence in Europe and North America. According to various studies, the regional prevalence of Alzheimer’s disease varies based on socio-economic differences as well as cultural variations. The disease is highly prevalent in North America and the United States alone accounts for over five million cases of Alzheimer's disease. As Alzheimer’s has a high prevalence amongst the elderly population, the growing elderly population in the region is a major concern for disease prevention. North America held the largest market share by value in the disease industry due to the availability of advanced healthcare infrastructure and drug development studies. Alzheimer's disease is more common in women than men as the former lives are more extended than the latter.
Alzheimer’s, studies have showcased that there is a prevalence in developed countries than in developing. This was attributed to differences in the level of exposure to cerebrovascular risk factors like hypertension, smoking, obesity, and diabetes. Europe had the second largest share of disease prevalence. Studies is Europe have equated high lower level of education to the high prevalence of the disease in the region.
Recent Alzheimer’s disease metric research has showcased a rapid rise in the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) rates globally, especially during the past three decades.
Asia Pacific region also followed the global trend as the prevalence of dementia seems to be higher in developed countries, like Japan and Korea, than in countries with low incomes in Asia. Japan accounts for the highest prevalence of Alzheimer’s disease in the region.
Currently, more than 25 million people in the world are affected by dementia, most of the patients suffering from Alzheimer’s disease, with around five million new cases occurring every year.
Various clinical trials for Alzheimer’s are being developed and researched by multifarious healthcare organizations and pharma companies. These industry segments are trying to understand the disease mechanism, disease treatment. As there is no treatment for Alzheimer’s, clinical trials are also being conducted for developing care pathway and slowing down the disease progression.
Despite the numerous constraints in hindrances, there have been some disease-modifying drugs that aim to slow down the progression of the disease. These drugs interfere with the progression of clinical symptoms, such as the accumulation of extracellular amyloid β plaques, together with intracellular neurofibrillary tangles, inflammation, cholesterol metabolism, iron deregulation, and oxidative damage, among other symptoms. The only aid so far has been significant changes in the lifestyle, including regular exercising. This is expected to pave way for the growth of the market for Alzheimer’s treatment in the healthcare industry.
Various therapies are being explored through clinical trials to find drugs against tau protein, and β-secretase (BACE), which are responsible for the tangles, plaques, and deterioration of memory and cognition by meditating neurotransmitters like glutamate and acetylcholine.
Although there has been no cure for the disease so far, the drug trial line up has been strong. Some of these drug’s trials might be successful and these drugs might reach the marketplace within the next decade. The Alzheimer’s disease market has been witnessing different key players conducting various trials.
One of the major industry players, Eli Lilly is conducting trials for six drugs that are in numerous phases of development. Another major healthcare conglomerate, Biogen is conducting clinical trials conducting trials for five drugs, which are in Phase 1, Phase 2, and Phase 3 clinical trials stages.
Other than Eli lily and Biogen, companies like Roche and Eisai are the major competitors in the industry in developing drugs and treatment methods for Alzheimer’s. Roche is developing a drug by using Genentech technology and is currently in phase 2 and phase 3 of the clinical trials. Eisai is also developing a treatment method in collaboration with Biogen.
Alzheimer’s disease is a devastating neurodegenerative disease leading to dementia. The disease industry has made significant progress over the last fifteen years. The causes of the disease are still not known, and the most prominent cause seems to be genetic and lifestyle factors. APOE4 gene is one of the most common genetic risks for the disease as there is high chance of disease development by lipid imbalances. There have been various competing theories based on amyloid, neurovascular, and tau to explain the factors causing the disease.
The cost of treatment for Alzheimer’s is very high. As the disease requires patient care as well as medical treatment. The Alzheimer’s therapeutic industry can be divided into pharmaceutical treatment as well as patient care.
The treatment cost for Alzheimer’s is the highest in the United States in the North America region. Alzheimer’s treatment market was valued between 200 to 300 billion USD in 2020 in the United States alone. In the coming years this cost is also projected to reach more than 1.1 trillion USD. With the high potential value for disease treatment, there is a wide opportunity for healthcare industries in drug development, and novel diagnostics methods. The industry is expected to see growth opportunities, which are directed towards understanding disease mechanisms related to genetic risk factors of Alzheimer’s, both for patient stratification and assessment of therapeutic efficacy in clinical trials. Organizational characteristics such as size and proprietary status are the major industry driving factors influencing the propensity to supply specialty care in dedicated units for Alzheimer’s disease. There is also growing opportunities in nursing care facilities, as they are moving toward providing specialty care units partly as a response to a growing demand by industry key segments and to maintain a competitive edge in a stiffer market.
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The rising initiatives by public and private organizations to increase awareness will also play a huge role in increasing the competition in the Alzheimer’s disease market. The competition in the global market is growing owing to the incorporation of niche technologies disease treatment. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Drug Class||
|Breakup by Diagnosis||
|Breakup by Therapeutic Channel||
|Breakup by Age||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Alzheimer’s Disease Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
22.214.171.124 Patent Status and Expiry
126.96.36.199 Timelines from Drug Development to Commercial Launch
188.8.131.52 New Drug Application
184.108.40.206.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
220.127.116.11 US FDA
18.104.22.168 EU EMA
22.214.171.124 INDIA CDSCO
126.96.36.199 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop- out Analysis
7.3 Awareness and Prevention Gaps
8 Current Scenario Evaluation and Regulatory Framework
8.1 Emerging Therapies and Clinical Trials
8.2 Patent Landscape
8.2.1 Patent Overview
188.8.131.52 Patent Status and Expiry
184.108.40.206 Timelines from Drug Development to Commercial Launch
220.127.116.11 New Drug Application
18.104.22.168.1 Documentation and Approval Process
8.3 Cost of Treatment
8.4 Regulatory Framework
8.4.1 Regulatory Overview
22.214.171.124 US FDA
126.96.36.199 EU EMA
188.8.131.52 INDIA CDSCO
184.108.40.206 JAPAN PMDA
9 Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop- out Analysis
9.3 Awareness and Prevention Gaps
10 Global Alzheimer’s Disease Treatment Market
10.1 Global Alzheimer’s Disease Treatment Overview
10.2 Global Alzheimer’s Market Treatment Analysis
10.2.1 Market Overview
10.2.1.1 Global Historical Alzheimer’s Disease Treatment Market Volume (2016-2022)
10.2.1.2 Global Forecast Alzheimer’s Disease Treatment Market Volume (2023-2031)
10.3 Global Alzheimer’s Treatment Market by Drug Class
10.3.1 Cholinesterase Inhibitors
10.3.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
10.4 Global Alzheimer’s Treatment Market by Diagnosis
10.4.1 Psychometric Diagnosis
10.4.2 Cerebrospinal Fluid Analysis
10.4.2.1 Amyloid And Tau Protein Analysis
10.4.2.1.1 Brain Imaging Tests
10.5 Global Alzheimer’s Treatment Market by Therapeutic Channel
10.6 Global Alzheimer’s Treatment Market by Age
10.7 Global Alzheimer’s Treatment Market by End User
10.7.1 Market Overview
10.7.1.1 Hospital Pharmacy
10.7.1.2 Retail Pharmacy
10.8 Global Alzheimer’s Treatment Market by Region
10.8.1 Market Overview
10.8.1.1 North America
10.8.1.3 Asia Pacific
10.8.1.4 Latin America
10.8.1.5 Middle East and Africa
11 North America Alzheimer’s Treatment Market
11.1 Market Share by Country
11.2 United States of America
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
12 Europe Alzheimer’s Treatment Market
12.1 Market Share by Country
12.2 United Kingdom
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5.1 Historical Trend (2016-2022)
12.5.2 Forecast Trend (2023-2031)
13 Asia Pacific Alzheimer’s Treatment Market
13.1 Market Share by Country
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6.1 Historical Trend (2016-2022)
13.6.2 Forecast Trend (2023-2031)
14 Latin America Alzheimer’s Treatment Market
14.1 Market Share by Country
14.2.1 Historical Trend (2016-2022)
14.2.2 Forecast Trend (2023-2031)
14.3.1 Historical Trend (2016-2022)
14.3.2 Forecast Trend (2023-2031)
14.4.1 Historical Trend (2016-2022)
14.4.2 Forecast Trend (2023-2031)
15 Middle East and Africa Alzheimer’s Treatment Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.2.1 Historical Trend (2016-2022)
15.2.2 Forecast Trend (2023-2031)
15.3 United Arab Emirates
15.3.1 Historical Trend (2016-2022)
15.3.2 Forecast Trend (2023-2031)
15.4.1 Historical Trend (2016-2022)
15.4.2 Forecast Trend (2023-2031)
15.5 South Africa
15.5.1 Historical Trend (2016-2022)
15.5.2 Forecast Trend (2023-2031)
16 Global Alzheimer’s Treatment Market Dynamics
16.1 Market Drivers and Constraints
16.2 SWOT Analysis
16.3 Porter’s Five Forces Model
16.4 Key Demand Indicators
16.5 Key Price Indicators
16.6 Industry Events, Initiatives & Trends
16.7 Value Chain Analysis
17 Supplier Landscape
17.1 F Hoffmann La Roche
17.1.1 Company Overview
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.2 H. Lundbeck
17.2.1 Company Overview
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.3 Zydus Lifesciences Ltd.
17.3.1 Company Overview
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.4 Pfizer Inc
17.4.1 Company Overview
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.5 Baxter International Inc.
17.5.1 Company Overview
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.6 Abbive, Inc.
17.6.1 Company Overview
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.7 Eisai Co. Ltd
17.7.1 Company Overview
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.8 Merz Pharma
17.8.1 Company Overview
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.9.1 Company Overview
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.10 Eli Lilly and Company
17.10.1 Company Overview
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.11 Teva Pharmaceutical Industries Ltd.
17.11.1 Company Overview
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.12 ONO Pharmaceutical Co. Ltd.
17.12.1 Company Overview
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.13 VTV Therapeutics
17.13.1 Company Overview
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.14.1 Company Overview
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
18 Global Alzheimer’s Treatment Market- Drug Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of USD 42.9 billion in 2022.
The market is likely to grow at a CAGR of 6.9% during forecast period of 2023-2031.
The market is expected to reach a value of USD 80.2 billion by 2031.
The market is driven by an ageing population, and the rise in immunological disorders is the main factor contributing to the disease's high prevalence.
Based on the drug classification the market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonist, and others.
Based on the diagnosis the market is segmented into Psychometric Diagnosis, Cerebrospinal Fluid Analysis, and Others.
The treatment channels in this market are public and private.
The different regions are North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
The key player in this market are F Hoffmann La Roche, H. Lundbeck, Zydus Lifesciences Ltd., Pfizer Inc, Baxter International Inc., Abbvie, Inc., Eisai Co. Ltd., Merz Pharma, AstraZeneca, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., ONO Pharmaceutical Industries Ltd., VTV Therapeutics, Biogen, among others.
First-line treatment for patients with mild-to-moderate Alzheimer's disease, cholinesterase inhibitor therapy with rivastigmine, donepezil, or galantamine is recommended.
Aducanumab, according to the FDA, lessens beta-amyloid plaques, which is probably going to prevent clinical decline brought on by Alzheimer's disease. The first medication to address the disease's fundamental biology.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.